Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer

被引：2
|
作者：
Chiorean, E. Gabriela
Whiting, Scott
Binder, Gary
Dranitsaris, George
Manax, Victoria
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Celgene Corp, Summit, NJ USA
[3] Augmentium Pharma Consulting, Toronto, ON, Canada
[4] Celgene, Summit, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.353
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
353
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china
    Cui, Jiujie
    Zhang, Xiaochen
    Qu, Shuli
    Wang, Liwei
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (04) : 691 - 697
  • [2] Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan
    Morimoto, Kosuke
    Moriwaki, Kensuke
    Kaneyasu, Takako
    Nakayama, Hitomi
    Shimozuma, Kojiro
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 54 - 60
  • [3] An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) plus gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study
    Lazzaro, Carlo
    Barone, Carlo
    Caprioni, Francesco
    Cascinu, Stefano
    Falcone, Alfredo
    Maiello, Evaristo
    Milella, Michele
    Pinto, Carmine
    Reni, Michele
    Tortora, Giampaolo
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (04) : 435 - 446
  • [4] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Han, Sung Yong
    Kim, Dong Uk
    Seol, Young Mi
    Kim, Suk
    Lee, Nam Kyung
    Hong, Seung Baek
    Seo, Hyung-Il
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (17) : 3718 - 3729
  • [5] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Sung Yong Han
    Dong Uk Kim
    Young Mi Seol
    Suk Kim
    Nam Kyung Lee
    Seung Baek Hong
    Hyung-Il Seo
    World Journal of Clinical Cases, 2020, (17) : 3718 - 3729
  • [6] nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Real life
    Cidon, E. Una
    Alonso, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S109 - S109
  • [7] Efficacy and safety of Nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
    Filipazzi, V.
    Dalu, D.
    Isabella, L.
    Tosca, N.
    Ferrario, S.
    Gambaro, A.
    Somma, L.
    Fasola, C.
    Pellegrini, I.
    Bombonati, G.
    Curcio, R.
    Damiani, E.
    Cattaneo, M. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Matters arising: On the cost-effectiveness for the Italian National Health Service of nab-paclitaxel plus gemcitabine vs gemcitabine alone in metastatic pancreatic cancer
    Lazzaro, Carlo
    JOURNAL OF THE EGYPTIAN PUBLIC HEALTH ASSOCIATION, 2024, 99 (01):
  • [9] ECONOMIC EVALUATION OF NAB-PACLITAXEL PLUS GEMCITABINE VERSUS GEMCITABINE ALONE FOR THE MANAGEMENT OF METASTATIC PANCREATIC CANCER IN GREECE
    Fragoulakis, V
    Papakostas, P.
    Pentheroudakis, G.
    Dervenis, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [10] A cost-utility analysis of gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer.
    Ko, Yoo-Joung
    Tam, Vincent Channing
    Mittmann, Nicole
    Pasteka, Mark
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345